Narayana Hrudayalaya LtdQ1 FY26

Narayana Hrudayalaya Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,741P/E: 44.1Market Cap: ₹38.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Narayana Hrudayalaya Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Narayana Hrudayalaya Ltd management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Narayana Hrudayalaya Ltd — get its next earnings analysis in your feed

How does Narayana Hrudayalaya Ltd rank vs peers in Healthcare Services?

Pro feature
ThisNarayana Hrudayalaya Ltd

How does Narayana Hrudayalaya Ltd rank in Healthcare Services?

Compare Narayana Hrudayalaya Ltd against every Healthcare Services company (Q1 FY26) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • KMC Speciality Hospitals (India) Ltd (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • KMC Speciality Hospitals (India) Ltd (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • Suven Life Sciences Ltd (Q1 FY22)

    The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…

  • Vimta Labs Ltd (Q3 FY25)

    Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →